Literature DB >> 10733541

A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.

M Malinchoc1, P S Kamath, F D Gordon, C J Peine, J Rank, P C ter Borg.   

Abstract

Transjugular intrahepatic portosystemic shunts (TIPS) may worsen liver function and decrease survival in some patients. The Child-Pugh classification has several drawbacks when used to determine survival in such patients. The survival of 231 patients at 4 medical centers within the United States who underwent elective TIPS was studied to develop statistical models to (1) predict patient survival and (2) identify those patients whose liver-related mortality post-TIPS would be 3 months or less. Among these elective TIPS patients, 173 had the procedure for prevention of variceal rebleeding and 58 for treatment of refractory ascites. Death related to liver disease occurred in 110 patients, 70 within 3 months. Cox proportional-hazards regression identified serum concentrations of bilirubin and creatinine, international normalized ratio for prothrombin time (INR), and the cause of the underlying liver disease as predictors of survival in patients undergoing elective TIPS, either for prevention of variceal rebleeding or for treatment of refractory ascites. These variables can be used to calculate a risk score (R) for patients undergoing elective TIPS. Patients with R > 1.8 had a median survival of 3 months or less. This model was superior to both the Child-Pugh classification, as well as the Child-Pugh score, in predicting survival. Using logistic regression and the same variables, we also developed a nomogram that indicates which patients survive less than 3 months. Finally, the model was validated among an independent set of 71 patients from the Netherlands. This Mayo TIPS model may predict early death following elective TIPS for either prevention of variceal rebleeding or for treatment of refractory ascites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733541     DOI: 10.1053/he.2000.5852

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  622 in total

Review 1.  Transjugular portosystemic stent shunt in treatment of liver diseases.

Authors:  M Schepke; T Sauerbruch
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Studies on avian erythrocyte metabolism--I. Procedure for separation and quantitation of the major phosphorylated metabolic intermediates by anion exchange chromatography.

Authors:  R E Isaacks; D R Harkness; G A Froeman; S A Sussman
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1976-01

3.  Value of the SOFA score as a predictive model for short-term survival in high-risk liver transplant recipients with a pre-transplant labMELD score ≥ 30.

Authors:  Harald Schrem; Melanie Reichert; Benedikt Reichert; Thomas Becker; Frank Lehner; Moritz Kleine; Hüseyin Bektas; Kai Johanning; Christian P Strassburg; Jürgen Klempnauer
Journal:  Langenbecks Arch Surg       Date:  2011-12-06       Impact factor: 3.445

4.  Current Management of Alcohol-Associated Liver Disease.

Authors:  Faisal A Siddiqi; Krishna C Sajja; Nyan L Latt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-11

5.  TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.

Authors:  Alexander S Rosemurgy; Emmanuel E Zervos; Whalen C Clark; Donald P Thometz; Thomas J Black; Bruce R Zwiebel; Bruce T Kudryk; L Shane Grundy; Larry C Carey
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

6.  Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension.

Authors:  Mubin I Syed; Hetal Karsan; Hector Ferral; Azim Shaikh; Uzma Waheed; Talal Akhter; Alan Gabbard; Kamal Morar; Robert Tyrrell
Journal:  World J Hepatol       Date:  2012-02-27

7.  Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Authors:  Pratima Sharma; Kathy Welch; Hero Hussain; Shawn J Pelletier; Robert J Fontana; Jorge Marrero; Robert M Merion
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

8.  Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; William E Mitch; Laurence S Magder; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; Charles D Howell; Jean-Pierre Raufman; Abbas Rana; John A Goss; Saira A Khaderi; John M Vierling
Journal:  Dig Dis Sci       Date:  2018-02-01       Impact factor: 3.199

9.  Using the Minimally Invasive Impella 5.0 via the Right Subclavian Artery Cutdown for Acute on Chronic Decompensated Heart Failure as a Bridge to Decision.

Authors:  Aditya Bansal; Jay K Bhama; Rajan Patel; Sapna Desai; Stacy A Mandras; Hamang Patel; Tyrone Collins; John P Reilly; Hector O Ventura; P Eugene Parrino
Journal:  Ochsner J       Date:  2016

10.  Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF).

Authors:  Justin L Grodin; Dianne Gallup; Kevin J Anstrom; G Michael Felker; Horng H Chen; W H Wilson Tang
Journal:  Am J Cardiol       Date:  2017-03-29       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.